I am trying to understand analysts revenue estimates ... this is what I have at ETrade.
Why are the revenue projections almost flat for the next four years? If FDA approves HIFU aren't we supposed to get at least 50% increase in revenues starting with year 2015 (US market is as big as Europe)? I am just trying to understand analysts rationale here. Any help out there?
You should look at the DATE of these estimates. That was before reimbursement approval in France, the standard of treatment recommendation for early stage prostate cancer of the European society of urologists and I think also. These estimates don't take into account these facties and others factor like FDA approval, Asia approval, treatment of other types of cancer, reimbursement approvals in other European countries, possible partnerships for the Asian or US market, ... My point is very clear: those estimates are history.